ATL1102 is being developed for relapsing MS by Antisense Therapeutics.
Current phase of trial: Phase 2
Type of MS: Relapsing MS
Find out more about ATL1102
How does ATL1102 work?
ATL1102 alters the behaviour of a type of immune cell (called a T cell), preventing it from entering the central nervous system.
It works in a similar way to the licensed treatment natalizumab (Tysabri).
How is ATL1102 taken?
ATL1102 is injected under the skin (subcutaneous injections).
Latest ATL1102 research
Phase 2 trial
In this phase 2 trial ATL1102 reduced new active lesions by 54% compared with placebo after 12 weeks. It was reported to be safe and well tolerated.
The trial involved 77 people with relapsing MS. Results were published in 2014.
What are the side effects of ATL1102?
ATL1102 was reported to be generally well tolerated, with some people experiencing mild to moderate redness of the skin surrounding the injection site. Some people were also found to have a decrease in the levels of a component of the blood associated with clotting (platelets) after treatment, but this returned to normal after the treatment.
Unlike natalizumab, ATL1102 treatment does not increase the risk of developing progressive multifocal leukoencephalopathy (PML).
How does ATL1102 compare with current therapies?
ATL1102 hasn’t yet been directly compared with other therapies for relapsing MS.
When is ATL1102 likely to become available?
Following the success of the phase 2 trial, the company developing ATL1102 (Antisense Therapeutics) submitted its findings to the US Food and Drug Administration (FDA), who responding positively to plans to start longer term and larger phase 2 trials.
Antisense Therapeutics announced in February 2016 that it intends to submit an application to the FDA so that it can begin larger trials. While this is an exciting development, no date has been set for this trial.
We will keep you informed on the progress of ATL1102.